Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Mass; Department of Medicine, The Mongan Institute, Massachusetts General Hospital, Boston, Mass.
Department of Pharmacy, University of Wisconsin Health, Madison, Wis.
J Allergy Clin Immunol Pract. 2021 Aug;9(8):3060-3068.e1. doi: 10.1016/j.jaip.2021.04.071. Epub 2021 May 21.
Treatment guidelines for pneumonia recommend beta-lactam antibiotic-based therapy. Although reported penicillin allergy is common, more than 90% of patients with reported penicillin allergy are not allergic.
We evaluated the association of a documented penicillin and/or cephalosporin (P/C) allergy to antibiotic use for the treatment of inpatient pneumonia.
This was a national cross-sectional study conducted among Vizient, Inc., network hospitals that voluntarily contributed data. Among hospitalized patients with pneumonia, we examined the relation of a documented P/C allergy in the electronic health record to prevalence of first-line beta-lactam antibiotic administration and alternative antibiotics using multivariable log-binomial regression with generalized estimating equations.
Of 2,276 inpatients receiving antibiotics for pneumonia at 95 U.S. hospitals, 450 (20%) had a documented P/C allergy. Compared with pneumonia patients without a documented P/C allergy, patients with a documented P/C allergy had reduced prevalence of first-line beta-lactam antibiotic use (adjusted prevalence ratio [aPR] 0.79; 95% confidence interval [95% CI] 0.69-0.89]). Patients with high-risk P/C reactions (n = 91) had even lower prevalence of first-line beta-lactam antibiotic use (aPR 0.47; 95% CI 0.35-0.64). Alternative antibiotics associated with a higher use in pneumonia patients with a documented P/C allergy included carbapenems (aPR 1.61; 95% CI 1.22-2.13) and fluoroquinolones (aPR 1.52; 95% CI 1.21-1.91).
Inpatients with documented P/C allergy and pneumonia were less likely to receive recommended beta-lactams and more likely to receive carbapenems and fluoroquinolones. Inpatient allergy assessment may improve optimal antibiotic therapy for the 20% of inpatients with pneumonia and a documented P/C allergy.
肺炎治疗指南推荐使用β-内酰胺类抗生素治疗。虽然报告的青霉素过敏很常见,但超过 90%的报告有青霉素过敏的患者并非过敏。
我们评估了电子病历中记录的青霉素和/或头孢菌素(P/C)过敏与住院肺炎患者抗生素治疗使用之间的关联。
这是一项在 Vizient,Inc. 网络医院进行的全国性横断面研究,这些医院自愿提供数据。在接受抗生素治疗肺炎的住院患者中,我们使用广义估计方程的多变量二项式回归,研究电子病历中记录的 P/C 过敏与一线β-内酰胺类抗生素给药和替代抗生素的使用之间的关系。
在 95 家美国医院接受抗生素治疗肺炎的 2276 名住院患者中,有 450 名(20%)有记录的 P/C 过敏。与没有记录的 P/C 过敏的肺炎患者相比,有记录的 P/C 过敏的患者使用一线β-内酰胺类抗生素的比例较低(调整后的流行率比[aPR]0.79;95%置信区间[95%CI]0.69-0.89)。有高风险 P/C 反应(n=91)的患者使用一线β-内酰胺类抗生素的比例更低(aPR 0.47;95%CI 0.35-0.64)。与有记录的 P/C 过敏的肺炎患者使用比例更高的替代抗生素包括碳青霉烯类(aPR 1.61;95%CI 1.22-2.13)和氟喹诺酮类(aPR 1.52;95%CI 1.21-1.91)。
有记录的 P/C 过敏和肺炎的住院患者更不可能接受推荐的β-内酰胺类药物,而更有可能接受碳青霉烯类和氟喹诺酮类药物。住院患者的过敏评估可能会改善 20%有记录的 P/C 过敏和肺炎的住院患者的最佳抗生素治疗。